By Karen Roman
Private equity company Jeito Capital said it is co-leading an oversubscribed €77.7 million (USD 84.8 million) Series A financing round in Augustine Therapeutics.
The founding will support Phase 2 of AGT-100216, Augustine’s main candidate for Charcot-Marie-Tooth disease and will contribute to pipeline expansion into cardio-metabolic and neurodegenerative diseases, it said.
The investment adds to Jeito’s expertise in neurological illnesses affecting large patient populations with unmet medical needs, the company stated.
“This commitment to the patients is at the core of our mission, and takes on its full meaning through this funding,” said Dr. Rafaèle Tordjman, MD, PhD, Jeito’s founder and CEO. “We are delighted to support Augustine and share our knowledge and experience with its talented teams, to advance novel therapeutics and contribute to the development of future innovative treatments.”
Contact:
